摘要
自1992年《生物多样性公约》确立事先知情同意原则以来,国际社会一直为建立更有效的生物材料国际保护机制而努力。本文认为在国际生物材料特殊保护机制确立之前,在充分发展的国际专利法体系中有所落实的事先知情同意原则,可以满足广大发展中国家的现实需要,是较为现实的选择。修订后的专利法可以要求生物材料的利用者在申请专利时,揭示实施发明方案所必需的生物材料的来源,并提交已获生物材料所有人事先知情同意的证据。不过,专利法不应让专利机关对事先知情同意的证据进行实质审查,也不应要求申请人提交利益分享方面的证据。
Since the Convention of Biological Diversity accepted the principle of prior informed consent（PIC） in 1992, international society has striven to establish an effective international sui generis regime for protecting biological/genetic materials. This article proposes that before finalization of the sui generis regime, developing countries can satisfy their desperate need for protection by adopting the principle of PIC in the well - developed international patent system. Patent law can impose on applicants the obligation to disclose sources of used biological materials and evidences of PIC in patent application. But this article argues that there is no need for patent office to verify the evidences of PIC and there is no need for applicants to provide evidence of benefit - sharing in their applications.
出处
《环球法律评论》
北大核心
2005年第5期571-580,共10页
Global Law Review
